Tenax Therapeutics (TENX) Return on Capital Employed (2011 - 2026)
Tenax Therapeutics (TENX) posted quarterly Return on Capital Employed of 60.0% for Q2 2026, down 2708.0% year-over-year from 2.3% in Q2 2025, and down 2.46% on a QoQ basis from 58.56% in Q1 2026.
Tenax Therapeutics (TENX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Tenax Therapeutics has reported Return on Capital Employed for 14 years, with the latest figure at 60.0% in Q2 2026.
- Return on Capital Employed for Q2 2026 came in at 60.0%, down 2708.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 60.0% (down 2708.0% YoY), and the FY2025 annual result was 60.43%, down 2105.0% from the prior year.
- Return on Capital Employed slipped to 60.0% in Q2 2026, from 58.56% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 496.95% in Q4 2022 and troughed at 1861.13% in Q1 2022.
- A 5-year average of 225.81% and a median of 53.42% in 2025 frame the typical range for Return on Capital Employed.
- The widest annual swing landed in 2022, when Return on Capital Employed sank 258417 bps; it then jumped 194246 bps in 2023.
- A 5-year view of Return on Capital Employed shows it stood at 496.95% in 2022, then sank by 128 bps to 137.96% in 2023, then soared by 85 bps to 20.84% in 2024, then slumped by 181 bps to 58.51% in 2025, then retreated by 3 bps to 60.0% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 60.0% in Q2 2026, 58.56% in Q1 2026, and 58.51% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 7.88% |
| 10 | Tenax Therapeutics | 79.33 Mn | 79.33 Mn | - | -60.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.00% |
| Mar 31, 2026 | -58.56% |
| Dec 31, 2025 | -58.51% |
| Sep 30, 2025 | -48.33% |
| Jun 30, 2025 | -32.93% |
| Mar 31, 2025 | -26.50% |
| Dec 31, 2024 | -20.84% |
| Sep 30, 2024 | -48.11% |
| Jun 30, 2024 | -172.16% |
| Mar 31, 2024 | -123.91% |
| Dec 31, 2023 | -137.96% |
| Sep 30, 2023 | 35.33% |
| Jun 30, 2023 | 37.36% |
| Mar 31, 2023 | 81.33% |
| Dec 31, 2022 | 496.95% |
| Sep 30, 2022 | -917.58% |
| Jun 30, 2022 | -1,148.98% |
| Mar 31, 2022 | -1,861.13% |
| Dec 31, 2021 | -555.85% |
| Sep 30, 2021 | 729.09% |